Drugs / Basimglurant
Trials 15
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 18 trials | ||||||
| Phase 1 | NCT02433093 | Apr → Sep 2015 | major depressive disorder | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT01873508 | Jun → Aug 2013 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT01665404 | Jul → Sep 2012 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT01629368 | Jun → Sep 2012 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT01592890 | Apr → May 2012 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT01483469 | Dec 2011 → Oct 2013 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT01368926 | Jun → Nov 2011 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT01045083 | Jan 2010 → Jun 2011 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 26 trials · 1 missed | ||||||
| Phase 2 | NCT05059327 | Mar 2022 → Feb 2025 | tuberous sclerosis | Noema Pharma AG | Completed | No outcome recorded |
| Phase 2 | NCT01750957 | Feb 2013 → Apr 2014 | fragile X syndrome | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 2 | NCT01517698 | May 2012 → Apr 2014 | fragile X syndrome | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 2 | NCT01437657 | Oct 2011 → Sep 2013 | major depressive disorder | Hoffmann-La Roche | Completed | Missed primary |
| Phase 2 | NCT01015430 | Nov 2009 → Jan 2011 | fragile X syndrome | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 2 | NCT00809562 | Mar 2009 → Feb 2011 | depressive disorder | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT05217628 | Jan 2022 → Feb 2027 expected | trigeminal neuralgia | Noema Pharma AG | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2022-10-18 | Noema Pharma AG | Regulatory Noema Pharma receives FDA Fast Track designation noemapharma.com ↗
Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS) indications, today announces that the US Food and Drug Administration (FDA) has granted Fast Track designation to its mGluR5 inhibitor basimglurant (NOE-101) for the treatment of trigeminal neuralgia (TN). |
| 2022-02-14 | Noema Pharma AG | Regulatory Noema Pharma announces FDA Investigational New Drug authorization for Phase 2b LibraTN study of mGluR5 inhibitor NOE-101 in trigeminal neuralgia noemapharma.com ↗
Noema Pharma, a Swiss-based clinical stage company targeting orphan central nervous system (CNS) diseases, today announces the U.S. Food and Drug Administration (FDA) has authorized an Investigational New Drug (IND) application to initiate a Phase 2b clincial trial of the mGluR5 inihibitor NOE-101 in trigeminal neuralgia (TN). |
All press releases naming this drug 5 releases
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 16 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Basimglurant | “Efficacy and Safety of Basimglurant as Adjunctive Therapy for Major Depression:” PMID 27304433 ↗ Jul 2016 |
| Known as | NOE-101 | “The study drug (NOE-101, basimglurant) is a potent inhibitor of metabotropic glutamate receptor 5 (mGluR5)” NCT05059327 ↗1“NOE-101” NCT05217628 ↗ |
| Known as | RG-7090 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3301626 ↗ |
| Known as | RO4917523 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01629368 ↗ |
| Known as | RO4917523-000 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3301626 ↗ |
| Known as | RO4917523-009 SULPHATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL3301626 ↗ |
| Action | Inhibit | “Antagonism of the postsynaptic metabotropic glutamate subtype 5 receptor” PMID 27304433 ↗ Jul 2016 |
| Modality | Small molecule | — CHEMBL3301626 ↗ |
| Route | Oral | “daily oral RO4917523” NCT00809562 ↗ |
| Target | GRM5 | “Metabotropic glutamate receptor 5 modulator” CHEMBL3301626 ↗ |